Eli Lilly and Company

NYSE (USD): Eli Lilly and Company (LLY)

Last Price

839.28

Today's Change

+41.83 (5.24%)

Day's Change

801.26 - 840.00

Trading Volume

3,936,354

Overview

Market Cap

797 Billion

Shares Outstanding

949 Million

Avg Volume

3,157,826

Avg Price (50 Days)

898.40

Avg Price (200 Days)

830.17

PE Ratio

87.78

EPS

9.57

Earnings Announcement

04-Feb-2025

Previous Close

797.45

Open

803.50

Day's Range

801.26 - 840.301

Year Range

561.65 - 972.53

Trading Volume

3,955,788

Price Change Highlight

1 Day Change

5.34%

5 Day Change

1.46%

1 Month Change

-8.06%

3 Month Change

-0.62%

6 Month Change

8.40%

Ytd Change

41.86%

1 Year Change

35.69%

3 Year Change

222.45%

5 Year Change

639.95%

10 Year Change

1129.07%

Max Change

29795.73%

News and Blogs

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Drug Manufacturers—General

Description:

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment